Phase 3 Schizophrenia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been formally diagnosed with schizophrenia through a full psychiatric assessment using the current standard diagnostic guidelines (DSM-5-TR).
• People whose schizophrenia was first diagnosed at least one year before the screening appointment for this trial.
• People whose schizophrenia has previously responded well to at least one antipsychotic medication (not including clozapine) taken at a proper treatment dose.

Who may not be able to join:

• People who have an unstable or poorly controlled ongoing health condition or serious illness — including certain neurological, liver, kidney, heart, digestive, lung, immune system, or hormonal conditions — or who have had cancer within the 30 days before the trial start date.
• People whose blood or other lab test results suggest a significant health condition that is poorly managed or has not yet been diagnosed.
• People who have previously been treated with a medication called clozapine specifically for treatment-resistant psychosis.
• People who have spent 30 or more consecutive days admitted to a psychiatric inpatient facility in the 90 days before the screening appointment (not counting stays for purely social reasons or participation in another clinical trial).
• People who have started or increased non-medication mental health therapy (such as talking therapies or other psychosocial treatments) within 3 weeks before screening, or where such changes are expected during the trial period.

Important: Always verify eligibility with the trial site directly before applying.